PU 23 |
Catalog No.GC50595
One-Click Copy Product Info
|
PU 23 is a kind of multidrug resistance protein 4 (MRP4) inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 817635-93-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
PU 23 is a kind of multidrug resistance protein 4 (MRP4) inhibitor[1]. MRP4 is an ATP-binding cassette (ABC) transporter, and MRP4 inhibition shows striking effects against cancer progression and drug resistance[2]. PU 23 shows high activity in improving cell sensibility to anticancer drug 6-mercaptopurine (6-MP)[1].
PU 23 (10μM; 72h) significantly inhibited the cell viability of HEK293/MRP4 cells with 6-MP. PU 23 (50μM; 2h) significantly increased the amount of 6-MP in HEK293/MRP4 cells[1].
References:
[1] Chen Y, Yuan X, Xiao Z, et al. Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening [J]. PLoS One, 2018, 13(10): e0205175.
[2] Wen J, Luo J, Huang W, et al. The pharmacological and physiological role of multidrug-resistant protein 4 [J]. The Journal of pharmacology and experimental therapeutics, 2015, 354(3): 358-375.
| Cell experiment [1]: | |
|
Cell lines |
HEK293/MRP4 cells |
|
Preparation Method |
Stable HEK293/MRP4 cells were seeded at 5×103 cells per well into duplicate 96-well plates. The following day, PU 23 was added to a single well and then 6-mercaptopurine (6-MP) was added to one plate to give a final concentration of 15μM. After 72h incubation, cell viability was assessed using sulforhodamine B. |
|
Reaction Conditions |
10μM; 72h |
|
Applications |
PU 23 showed high activity with an inhibition rate of 81.71% with 6-MP and only 15.26% without 6-MP, while the inhibition of 6-MP was only 23.48%. PU 23 reduced resistance to anticancer agent 6-MP. |
References: [1] Chen Y, Yuan X, Xiao Z, et al. Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening [J]. PLoS One, 2018, 13(10): e0205175. | |
| Cas No. | 817635-93-1 | SDF | |
| Canonical SMILES | O=C(NC(=S)NC1=CC=C(C=C1)[S](=O)(=O)NCC1=CC=CC=C1)C1=CC=CC=C1 | ||
| Formula | C21H19N3O3S2 | M.Wt | 425.52 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3501 mL | 11.7503 mL | 23.5007 mL |
| 5 mM | 470 μL | 2.3501 mL | 4.7001 mL |
| 10 mM | 235 μL | 1.175 mL | 2.3501 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)